Diadema Partners LP Makes New $650,000 Investment in Nektar Therapeutics (NASDAQ:NKTR)

Diadema Partners LP purchased a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 698,919 shares of the biopharmaceutical company's stock, valued at approximately $650,000. Diadema Partners LP owned approximately 0.38% of Nektar Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of NKTR. Renaissance Technologies LLC grew its stake in shares of Nektar Therapeutics by 17.5% during the fourth quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company's stock valued at $3,637,000 after buying an additional 583,153 shares during the last quarter. State Street Corp boosted its stake in Nektar Therapeutics by 11.9% in the 3rd quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company's stock worth $4,349,000 after purchasing an additional 355,759 shares in the last quarter. Altium Capital Management LLC increased its position in shares of Nektar Therapeutics by 26,172.0% during the fourth quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company's stock valued at $2,790,000 after acquiring an additional 2,988,581 shares in the last quarter. Monaco Asset Management SAM increased its holdings in Nektar Therapeutics by 1.8% in the 4th quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company's stock worth $1,891,000 after buying an additional 35,648 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Nektar Therapeutics by 29.5% in the 4th quarter. JPMorgan Chase & Co. now owns 1,182,995 shares of the biopharmaceutical company's stock worth $1,100,000 after buying an additional 269,695 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on NKTR. Oppenheimer upgraded Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price objective for the company in a research note on Friday, March 14th. B. Riley began coverage on Nektar Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price target for the company. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a report on Thursday, March 13th. HC Wainwright reiterated a "buy" rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research report on Thursday, March 13th. Finally, StockNews.com started coverage on Nektar Therapeutics in a report on Wednesday, April 16th. They set a "hold" rating for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $4.50.

Nektar Therapeutics Stock Up 5.0 %

Shares of Nektar Therapeutics stock traded up $0.04 during trading on Friday, reaching $0.78. The company's stock had a trading volume of 3,162,228 shares, compared to its average volume of 1,817,051. The company has a 50-day simple moving average of $0.74 and a two-hundred day simple moving average of $0.95. Nektar Therapeutics has a 1-year low of $0.43 and a 1-year high of $1.93. The company has a market cap of $144.25 million, a price-to-earnings ratio of -0.92 and a beta of 0.69.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.33. The business had revenue of $29.18 million during the quarter, compared to the consensus estimate of $36.65 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. As a group, analysts anticipate that Nektar Therapeutics will post -0.72 earnings per share for the current year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.